Immunomedics, GE Healthcare collaborate to evaluate peptide labeling technologies

NewsGuard 100/100 Score

Immunomedics, Inc. (Nasdaq:IMMU) and GE Healthcare, a business unit of General Electric Company (NYSE:GE), announced today that they have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method. Terms of the agreement were not disclosed, but GE Healthcare will fund all costs related to this collaboration.

"As reported at the recent annual meeting of the Society of Nuclear Medicine, we have developed a facile and rapid method to label peptides with fluorine-18 (F-18), a radionuclide used in positron-emission imaging," stated Cynthia L. Sullivan, President and CEO of Immunomedics, Inc. "We look forward to GE Healthcare's collaboration with us," added Ms. Sullivan.


Immunomedics, Inc. and GE Healthcare


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI in healthcare shows promise in trials but needs real-world testing to ensure effectiveness